Drugs / TRG001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07009184 | Dec 2025 → Dec 2026 expected | carcinoma | Radboud University Medical Center | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06959706 Background | May 2025 → Sep 2026 overdue | cancer | Tagworks Pharmaceuticals BV | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRG001 | “TRG001 is a small molecule tetrazine trigger that reacts with \[111In\]In-TGW211-DC in blood and extracellular space thus releasing a fast clearing \[111In\]In-DOTA containing...” NCT07009184 ↗1“TGW101 is a combination product comprising a chemically cleavable diabody drug conjugate (TGW101-ADC) and a corresponding small molecule chemical trigger (TRG001) administered...” NCT06959706 ↗ |
| Modality | Small molecule | “small molecule chemical trigger” NCT06959706 ↗ |
| Route | Intravenous | “intravenous administration of TRG001 in escalating dose levels.” NCT07009184 ↗ |